



TREATMENT OPTIONS OVERVIEW

STAGE R/R MM

What's possible for *Confidential Patient*.

A working brief on 7 FDA-approved treatments, 6 matched clinical trials, and the questions worth raising at the next oncology visit.

PATIENT

50-59 • Male

DIAGNOSIS

By Disease Stage, R/R
MM

ECOG

0 • Fully Active

01 • DIAGNOSIS

Understand My Diagnosis

The clinical picture in plain language.

“

DIAGNOSTIC SUMMARY

Multiple myeloma is a cancer of plasma cells, a type of white blood cell found in bone marrow. In newly diagnosed multiple myeloma, the cancer has just been identified and treatment is being planned.

STAGE R/R MM | ECOG 0

Stage R/R MM | ECOG 0

Your cancer is classified as relapsed or refractory, meaning it has returned or did not respond to initial treatment. Your ECOG score of 0 means you are fully active and able to carry on all normal activities without restriction, which gives you more treatment options.

NEXT STEP: BIOMARKER TESTING

Next Step: Biomarker Testing

No specific biomarkers have been identified yet. Testing for CD38 and other markers may help guide treatment choices.

SHOWING OPTIONS FOR

BY DISEASE STAGE

STAGE R/R MM

1L

FDA-Approved Treatment Options

The 7 treatments below include FDA-approved therapies for multiple myeloma. Some are used in first-line treatment, while others are reserved for relapsed or refractory disease.

TARGETED THERAPY

Daratumumab / Darzalex Faspro ★ BEST · PFS, ORR, DOR


⚠️ REFRACTORY ONLY

Daratumumab

Daratumumab is a monoclonal antibody that targets CD38, a protein found on myeloma cells. It is given as an injection under the skin and helps the immune system find and destroy cancer cells.



Out of 100 patients like you, tumor shrank in 92:



●●● MODERATE

Infusion reactions Low blood counts
Fatigue Respiratory infections

SIDE EFFECT PROFILE


Subcutaneous injection with monitoring for infusion reactions and low blood counts

STANDARD THERAPY

Velcade

Bortezomib


Bortezomib is a proteasome inhibitor that blocks the breakdown of proteins inside myeloma cells, causing them to die. It is given as an injection under the skin or into a vein.



How long it keeps working
DURATION OF RESPONSE

—

Out of 100 patients like you, tumor shrank in 38:



●●● MODERATE

Peripheral neuropathy Low blood counts
Nausea Fatigue

SIDE EFFECT PROFILE

Injection with monitoring for nerve damage and low blood counts


STANDARD THERAPY

Thalomid ★ BEST · CR

⚠️ REFRACTORY ONLY


Thalidomid

Thalidomide is an oral immunomodulatory drug that helps the immune system attack myeloma cells and blocks the blood supply to tumors. It is taken as a daily capsule.



✓ Complete response no detectable cancer 6.00%

Out of 100 patients like you, tumor shrank in 32:



●●● MODERATE

Birth defect risk Blood clots Drowsiness
Constipation

SIDE EFFECT PROFILE


Daily oral medication with monitoring for birth defects and blood clots

CHEMOTHERAPY

Doxorubicin Hydrochloride

Doxorubicin Hydrochloride

Doxorubicin is a chemotherapy drug that interferes with DNA in cancer cells to stop them from growing. It is given through an intravenous infusion.



●●● MODERATE-HIGH

Heart damage risk Low blood counts
Hair loss Nausea

SIDE EFFECT PROFILE

IV infusion with monitoring for heart damage and low blood counts

CHEMOTHERAPY


Cyclophosphamide

Cyclophosphamide

Cyclophosphamide is a chemotherapy drug that damages DNA in cancer cells. It is used in combination regimens for multiple myeloma and given as an oral tablet or IV infusion.



Out of 100 patients like you, tumor shrank in 43:



●●● MODERATE-HIGH

Low blood counts Bladder irritation
Nausea Hair loss

SIDE EFFECT PROFILE

Oral or IV chemotherapy with monitoring for bladder irritation and low blood counts

STANDARD THERAPY


Alkeran for Injection / Evomela ★ BEST · OS

Melphalan Hydrochloride

Melphalan is a chemotherapy drug used in high doses before stem cell transplant or in lower doses for treatment. It works by damaging DNA in myeloma cells.



Out of 100 patients like you, tumor shrank in 50:



●●● MODERATE-HIGH

Low blood counts Secondary cancer risk
Nausea Mouth sores

SIDE EFFECT PROFILE


IV or oral chemotherapy with monitoring for low blood counts and secondary cancers

CHEMOTHERAPY


Droxil

Doxorubicin Hydrochloride Liposome

Liposomal doxorubicin is a form of chemotherapy wrapped in fat particles that helps it stay in the body longer and target tumor cells more effectively. It is given as an IV infusion.



Out of 100 patients like you, tumor shrank in 44:



●●● MODERATE-HIGH

Hand-foot syndrome Mouth sores
Low blood counts Infusion reactions

SIDE EFFECT PROFILE

IV infusion with reduced heart risk compared to standard doxorubicin but monitoring still needed

Clinical Trial Options Near Me

6 actively recruiting trials at facilities within 50 miles of ZIP 30322

✓ Clinical trials explained

- **No placebos:** Every patient gets active treatment
- **Trial pays:** Experimental drug + all study costs
- **You pay:** Standard care deductible only (same as SOC drugs)
- **Includes SOC:** Trials marked ✓ SOC include a proven standard treatment — lower risk, guaranteed active therapy

NCT07280013 PHASE 1

DISTANCE

Cemsidomide + Elranatamab Study

5 mi

C4 Therapeutics, Inc. · Winship Cancer Institute, Emory University, Atlanta, Georgia

This early-phase study tests a new combination of cemsidomide and elranatamab in myeloma that has returned or stopped responding to prior treatment. Both drugs work through different mechanisms to attack cancer cells.

YOUR LIKELY ELIGIBILITY

- ✓ AGE 18+
- ✓ ECOG 0-2
- ? PRIOR LINES OF THERAPY
- ? PRIOR BCMA OR CAR-T EXPOSURE

Early-phase trial — experimental drug only, no guaranteed standard treatment.

✓ STUDY COVERS Cemsidomide, Elranatamab, all study-related visits

17 FOLLOW-UP Regular monitoring during treatment

SITES Winship Cancer Institute, Emory University, Atlanta, Georgia (5 mi)

NCT07116616 PHASE 1/2

DISTANCE

mRNA-2808 Vaccine Study

5 mi

ModernaTX, Inc. · Emory University Hospital, Atlanta, Georgia

This study tests an experimental mRNA vaccine designed to train the immune system to recognize and attack myeloma cells. It is for patients whose cancer has returned or not responded after standard treatments.

YOUR LIKELY ELIGIBILITY

- ✓ AGE 18+
- ? PRIOR PROTEASOME INHIBITOR EXPOSURE
- ? PRIOR IMiD EXPOSURE
- ? PRIOR ANTI-CD38 ANTIBODY EXPOSURE
- ? MEASURABLE DISEASE STATUS

Early-phase trial — experimental drug only, no guaranteed standard treatment.

✓ STUDY COVERS mRNA-2808, all study-related visits

17 FOLLOW-UP 2 years monitoring

SITES Emory University Hospital, Atlanta, Georgia (5 mi)

NCT06106945 PHASE 1/2

DISTANCE

AZD0305 Combination Study

5 mi

AstraZeneca · Research Site, Atlanta, Georgia

This modular study tests AZD0305 alone or combined with other myeloma drugs including elranatamab, pomalidomide, or dexamethasone. Different patient groups may receive different combinations based on their prior treatment history.

YOUR LIKELY ELIGIBILITY

- ✓ AGE 18+
- ✓ ECOG 0-1 OR 0-2
- ? MEASURABLE DISEASE STATUS
- ? ORGAN FUNCTION
- ? PRIOR THERAPIES

Early-phase trial — experimental drug only, no guaranteed standard treatment.

✓ STUDY COVERS AZD0305, Elranatamab, Pomalidomide, Dexamethasone, all study-related visits

17 FOLLOW-UP Regular monitoring per module

SITES Research Site, Atlanta, Georgia (5 mi), Research Site, Nova Scotia

NCT07409246 PHASE 1

DISTANCE

ABBV-438 First-in-Human Study

40 mi

AbbVie · City Of Hope - Atlanta. /ID# 280294, Newnan, Georgia

This first-in-human study tests ABBV-438, a completely new experimental drug for relapsed or refractory myeloma. As the first human trial, its main goal is to find a safe dose and see early signs of activity.

YOUR LIKELY ELIGIBILITY

- ✓ AGE 18+
- ✓ RELAPSED OR REFRACTORY DISEASE
- ? MEASURABLE DISEASE STATUS
- ? PRIOR TREATMENT DETAILS

Early-phase trial — experimental drug only, no guaranteed standard treatment.

✓ STUDY COVERS ABBV-438, all study-related visits

17 FOLLOW-UP Regular safety monitoring

SITES City Of Hope - Atlanta. /ID# 280294, Newnan, Georgia (40 mi), The Cancer Institute Hospital Of JFCR /ID# 279069, Koto-ku, Tokyo

NCT05827016 PHASE 3 INCLUDES SOC

DISTANCE

Iberdomide vs Lenalidomide Maintenance

5 mi

Bristol-Myers Squibb · The Winship Cancer Institute of Emory University, Atlanta, Georgia

This phase 3 study compares iberdomide to lenalidomide as maintenance therapy after stem cell transplant in newly diagnosed myeloma. Maintenance therapy is given to keep cancer in remission longer.

YOUR LIKELY ELIGIBILITY

- ✓ AGE 18+
- ✓ ECOG 0-2
- ? PRIOR INDUCTION THERAPY
- ? STEM CELL TRANSPLANT COMPLETED
- ? TIME SINCE TRANSPLANT

This trial guarantees you receive active lenalidomide therapy (experimental or standard).

✓ STUDY COVERS Iberdomide, Lenalidomide, all study-related visits

17 FOLLOW-UP Until disease progression or unacceptable toxicity

SITES The Winship Cancer Institute of Emory University, Atlanta, Georgia (5 mi), Hospital Italiano de Buenos Aires, Ciudad Autonoma Buenos Aires, Buenos Aires F.D., "Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"", Ciudad Autonoma Buenos Aires, Buenos Aires F.D.

NCT06271252 PHASE 1

DISTANCE

OriCAR-017 CAR-T Cell Study

5 mi

OriCell Therapeutics Co., Ltd. · Northside Hospital, Atlanta, Georgia

This study tests OriCAR-017, a CAR-T cell therapy targeting GPRC5D, a protein on myeloma cells. CAR-T uses your own immune cells, modified in a lab, to find and destroy cancer.

YOUR LIKELY ELIGIBILITY

- ✓ AGE 18-75
- ✓ ECOG STATUS ACCEPTABLE
- ? PRIOR LINES OF THERAPY
- ? BCMA THERAPY EXPOSURE
- ? MEASURABLE DISEASE STATUS
- ? ORGAN FUNCTION

Early-phase trial — experimental drug only, no guaranteed standard treatment.

✓ STUDY COVERS OriCAR-017, all study-related visits

17 FOLLOW-UP Long-term follow-up for safety and durability

SITES Northside Hospital, Atlanta, Georgia (5 mi)

Questions to Ask My Care Team

Copy-paste ready for your appointment — bring a family member or friend for support



About Your Diagnosis

03 QUESTIONS

- What does 'relapsed or refractory' mean for my newly diagnosed status?
- Should I get additional biomarker testing like CD38, FISH, or cytogenetics?
- How does my ECOG score of 0 affect my treatment options?



About Treatment Options

03 QUESTIONS

- Is daratumumab appropriate for me as first-line therapy, or only if my disease becomes refractory?
- What combination would you recommend: bortezomib-based, immunomodulatory-based, or daratumumab-based?
- Would high-dose melphalan with stem cell transplant be part of my initial treatment plan?



About Clinical Trials

03 QUESTIONS

- NCT05827016: Am I eligible for the maintenance trial if I haven't had a stem cell transplant yet?
- NCT07280013: Would I need to have received 2-4 prior therapies to join this study?
- NCT06271252: Is CAR-T therapy appropriate for first-line treatment, or only after other therapies fail?

“Need help understanding these options?”

 17 Book a Meeting with Trial Triage

TrialTriage

Data sources: ClinicalTrials.gov, Efficacy Database, Evidence-Based Oncology Guidelines

This report is for educational purposes and does not constitute medical advice. Always consult with qualified healthcare professionals regarding your treatment decisions.